Effect of glimepiride and glibenclamide on S-warfarin 7-hydroxylation by human liver microsomes, recombinant human CYP2C9.1 and CYP2C9.3

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 9, 2006, Pages 1983-1985

  Iwakawa, Seigo ^a   Miyashita, Kenji ^a   Hashimoto, Yasuaki ^b   Kuroda, Tsutomu ^b  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^b Miki City Hospital   (Japan)

Author keywords

CYP2C9; Drug interaction; Drug metabolism; Glimepiride; Liver microsome; Warfarin

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; RECOMBINANT HUMAN CYTOCHROME P450 2C9 1; RECOMBINANT HUMAN CYTOCHROME P450 2C9 3; RECOMBINANT PROTEIN; SULFAPHENAZOLE; TOLBUTAMIDE; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; GENOTYPE; HUMAN; HUMAN CELL; HYDROXYLATION; KINETICS; LIVER MICROSOME;

ARYL HYDROCARBON HYDROXYLASES; CELL SURVIVAL; GLYBURIDE; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; RECOMBINANT PROTEINS; SULFONYLUREA COMPOUNDS; WARFARIN;

EID: 33748369900     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.1983     Document Type: Article

References (16)

1. Rettie A. E., Korzekwa K. R., Kunze K. L., Lawrence R. F., Eddy A. C., Aoyama T., Gelboin H. V., Gonzalez F. J., Trager W. F., Chem. Res. Toxicol., 5, 54-59 (1992).
2. Kaminsky L. S., Zhang Z. Y., Pharmacol. Ther., 73, 67-74 (1997).
3. Sullivan-Klose T. H., Ghanayem B. I., Bell D. A., Zhang Z. Y., Kaminsky L. S., Shenfield G. M., Miners J. O., Birkett D. J., Goldstein J. A., Pharmacogenetics, 6, 341-349 (1996).
4. Romkes M., Faletto M., Blaisdell J. A., Raucy J. L., Goldstein J. A., Biochemistry, 30, 3247-3255 (1991).
5. Rettie A. E., Wienkers L. C., Gonzalez F. J., Trager W. F., Korzekwa K. R., Pharmacogenetics, 4, 39-42 (1994).
6. Imai J., Ieiri I., Mamiya K., Miyahara S., Furuumi H., Nanba E., Yamane M., Furumaki Y., Ninomiya H., Tashiro N., Otsubo K., Higuchi S., Pharmacogenetics, 10, 85-89 (2000).
7. Dickmann L. J., Rettie A. E., Kneller M. B., Kim R. B., Wood A. J., Stein C. M., Wilkinson G. R., Schwarz U. I., Mol. Pharmacol., 60, 382-387 (2001).
8. Kidd R. S., Curry T. B., Gallagher S., Edeki T., Blaisdell J., Goldstein J. A., Pharmacogenetics, 11, 803-808 (2001).
9. Si D., Guo Y., Zhang Y., Yang L., Zhou H., Zhong D., Pharmacogenetics, 14, 465-469 (2004).
10. Niemi M., Cascorbi I., Timm R., Kroemer H. K., Neuvonen P. J., Kivisto K. T., Clin. Pharmacol. Ther., 72, 326-332 (2002).
11. Kim K. A., Park J. Y., Drug Metab. Dispos., 31, 1090-1092 (2003).
12. Yamazaki H., Shimada T., Biochem. Pharmacol., 54, 1195-1203 (1997).
13. Takahashi H., Kashima T., Nomoto S., Iwade K., Tainaka H., Shimizu T., Nomizo Y., Muramoto N., Kimura S., Echizen H., Pharmacogenetics, 8, 365-373 (1998).
14. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T., J. Pharmacobio-Dyn., 4, 879-885 (1981).
15. Dixon M., Biochem. J., 55, 170-171 (1953).
16. Wang J.-S., Wen X., Backman J. T., Neuvonen P. J., J. Pharmaol. Exp. Ther., 302, 43-49 (2002).